Associated Papers
A droplet digital LAMP-based lab-on-a-disc system for multiplex allele-specific detection of tumor-derived DNA mutations.
Lu H et al.
Biosensors & Bioelectronics, 2026
Analytical and clinical validation of a novel CE-IVD kit for PIK3CA hotspot mutations in liquid biopsy samples.
Stergiopoulou D et al.
The Journal of Liquid Biopsy, 2026
Genetic analysis of key players in PI3K signaling cascade of colorectal carcinoma.
Pervaiz H et al.
Scientific Reports, 2026
Clinical and Genetic Landscape of Glioblastoma, IDH-Wildtype With FGFR Gene Family Alterations.
Kegoya Y et al.
Cancer Science, 2026
PIK3CA mutation in ER-negative and HER2-positive breast cancer with apocrine differentiation.
Nozaki F et al.
Breast Cancer (tokyo, Japan), 2026
Differentiated In Vitro Efficacy of BYL719, ARQ092, and Rapamycin on Fibroblasts Isolated From a Chinese PIK3CA-Related Overgrowth Spectrum Individual With a Novel Variant.
Xiong F et al.
American Journal of Medical Genetics. Part A, 2026
The oncogenome of the domestic cat.
Francis BA et al.
Science (new York, N.y.), 2026
Characterization of the somatic landscape and transcriptional profile of breast tumors from 748 Hispanic/Latina women in California.
Ding YC et al.
Medrxiv : the Preprint Server for Health Sciences, 2026
Coexistent PTEN and PIK3CA alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibition.
Solomon H et al.
Biorxiv : the Preprint Server for Biology, 2026
Pan-cancer inference and validation of hypermorphic, hypomorphic and neomorphic mutations.
Tagore S et al.
Nature Genetics, 2026
Deciphering the Genomic Landscape of Oropharyngeal Squamous Cell Carcinoma: Distinct Mutation Patterns in Disease.
Hsia B et al.
Life (basel, Switzerland), 2026
Molecular Landscape of Resected Thymomas: Insights from Mutational Profiling.
Frasca L et al.
Diagnostics (basel, Switzerland), 2026
PIK3CA Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted Patients.
Rossi S et al.
Biomedicines, 2026
Attenuated Li-Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report.
Kasahara Y et al.
Familial Cancer, 2026
Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years.
Diab E et al.
Breast (edinburgh, Scotland), 2026
Alpelisib, a PI3Kα inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes.
Pithadia DJ et al.
Blood Vessels, Thrombosis & Hemostasis, 2026
Detection of Cancer-Associated Mutations Using Primer Exchange Reaction-Based Signal Amplification and Lateral Flow Assays.
Kocabey S et al.
Small Science, 2026
Concordance of Genomic Alterations in Ovarian Cancer Tissues and Circulating-Tumor DNA: A Pilot Study.
Kang B et al.
International Journal of Molecular Sciences, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer.
Sambath J et al.
Molecular Oncology, 2026
Molecular Characterization of Vascular Anomalies Tissues Guides Clinical Diagnosis.
Henslee SB et al.
Lymphatic Research and Biology, 2026
A new functional assay reveals that membrane binding is critical for overactivation of the phosphoinositide 3-kinase H1047R mutant.
Papafotika A et al.
The Journal of Biological Chemistry, 2026
A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.
Lou H et al.
Medrxiv : the Preprint Server for Health Sciences, 2026
Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets.
Jang H et al.
Communications Chemistry, 2026
"Beyond HER2 overexpression: somatic alterations in HER2 and PI3K genes in HER2-high and HER2-low/TNBC breast cancer.
Thakur T et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
Aging, dauer, and stature phenotypes are conferred by structure-directed missense mutations in the endogenous AGE-1/phosphatidylinositol 3-kinase catalytic subunit.
Wu Y et al.
Biorxiv : the Preprint Server for Biology, 2026
Molecular characterization of clear cell adenocarcinoma of the urinary bladder.
Jha S et al.
Histopathology, 2026
A comparative analysis of mutational profiles between triple-negative breast cancer and non-triple-negative breast cancer.
Li W et al.
Discover Oncology, 2026
Remarkable response of gastric adenocarcinoma with FGFR2-TRIM44 fusion to pemigatinib: a case report.
Fujiwara M et al.
Japanese Journal of Clinical Oncology, 2026
Comprehensive Genomic Characterization of 102 Cervical Adenocarcinoma Tumors.
Toromani G et al.
Medicina (kaunas, Lithuania), 2026
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Juric D et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Proteoform medicine: characterizing and targeting protein forms in human disease.
Korchak JA et al.
Nature Reviews. Genetics, 2026
Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.
Nashier D et al.
Archives of Medical Research, 2026
GenBlosum: On Determining Whether Cancer Mutations Are Functional or Random.
Leyva A et al.
Genes, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.
Liu X et al.
Annual Review of Pharmacology and Toxicology, 2026
Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers.
Gencel-Augusto J et al.
Advances in Biological Regulation, 2026
Bridge Capture Permits Cost-Efficient, Rapid, and Sensitive Molecular Precision Diagnostics.
Adamusová S et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Phylogenetic analysis of paired breast carcinomas identifies genetic events associated with clonal recurrence and invasive progression.
Kader T et al.
The Journal of Pathology, 2026
Vascular malformations: from genetics to therapeutics.
Morin G et al.
Embo Molecular Medicine, 2026